Vascular Graft Solutions’ Post

Congratulations to Prof. Dr. Marija Zdravkovic MD, PhD, FESC, Dr. Davor Mrda, Dr. Viseslav Popadic, Dr. Djordje Marinkovic, Dr. Jovana Lalatović and staff at the University Hospital Medical Center Bežanijska Kosa and SCIRENT Clinical Research and Science for the first #MobiusHD implant!  MobiusHD® is a novel, investigational device designed to restore baroreceptor sensitivity, amplify the #baroreflexresponse and improve cardiovascular function in symptomatic #heartfailure patients despite optimal drug treatment. Learn more about  #MobiusHD and #enrollment in the #clinicalstudy at www.vasculardynamics.com (Mobius HD is an investigational device and not for sale in any geography.)

📣We share the #Review "Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems" 🧐by Stefano Marletta, Nicola Fusco, et al. University of Verona, Università degli Studi di Milano Access the full paper here👉 https://lnkd.in/gTU4B5dc #PDL1 #immunohistochemistry #immunotherapy #clones #scores Journal of Personalized Medicine MDPI

Our Study titled "Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis" has been published online Important Highlights: • Explored everolimus, an mTOR inhibitor, for its effect on NF-1 lesion size via meta-analysis. • Four phase II single arm trials with 83 patients showed no significant effect of oral everolimus on lesion size reduction. • Safety discrepancies across studies raise concerns about everolimus' overall safety in NF-1 patients. • Emphasizes the necessity for more research, personalized treatments, and larger standardized trials in NF-1. you can read the full text here: https://lnkd.in/dMDPY_g2 Thanks to Global Alliance of Young Researchers thanks to Dr Mostafa Meshref , Dr Abdulqadir Nashwan for their great Efforts LinkedIn Ahmed Nada #Everolimus #Research #NF1

🔬New Article Co-authored by UNC and Duke Researchers Dougald Monroe, PhD, from UNC Department of Medicine and Ammon Fager, MD, PhD, from Duke Department of Medicine have co-authored a new article titled, “Stopping the bleed when the platelets don’t stick.” The publication details a bifunctional antibody that brings factor VIIa, which kickstarts platelet activation, to the surface of activated platelets. The antibody is currently in clinical trials for the treatment of a platelet adhesion disorder called Glanzmann thrombasthenia. https://ow.ly/MNJv50QHkWn #UNC #DeptofMed #unchealth #platelets #antibody #medicalresearch #clinicaltrials #Glanzmannthrombasthenia #medicalarticle

**Just released, online first** A new study from the AO Spine Knowledge Forum Degenerative, led by Xiaolong Chen and Ashish Diwan, compared the clinical effectiveness of reduction and fusion with in situ fusion in patients with degenerative lumbar spondylolisthesis. What did the findings reveal? Significantly longer operating times in the reduction and fusion group compared to in situ. But they also suggest no substantial superiority of reduction and fusion in terms of improving the prognosis of DLS patients. Read paper in European Spine Journal 🔗 https://brnw.ch/21wF30q #spine #aospine #degenerative #research #spondylolisthesis #lumbar

The definitive Conference & Course for 2024. We all have patients in our practice who are not suitable for surgery for a variety of reasons and all unfortunately are often let down by being consigned to prescription drugs until they can’t cope anymore. There are potential alternatives available to help these patients live a more manageable and comfortable life with a strong and ever growing evidence base. However, like most tools knowing when to do something and when not to is key. When you decide to act it is not just choosing the correct biomedicine that matters but then also the nuances to achieve success this includes many things: - Type of the intervention - Dose of the intervention - US or image guidance - Preparation of your patient and the substrate for optimal results (prehab) - post procedure care (rehab/outcome optimisation) Without a sight of the whole patient journey you do a half-job and a disservice to your patients and yourself. Come and learn from the best in the business in London this year 🙌🏼💪🏼🧐 https://lnkd.in/eWHyQxRV

Shugan Hewei therapy (SHT), a traditional Chinese medicine method, is widely recognized for its role in soothing the liver and harmonizing the stomach, particularly in treating chronic atrophic gastritis (CAG). Despite its popularity, the clinical effectiveness and safety of SHT have remained unclear—until now. This Chinese Medicine and Culture study, which analyzed data from 27 randomized controlled trials involving 2,441 patients, demonstrates that SHT is more effective and safer than control interventions, including western medicine and Chinese patent medicine. The therapy significantly improved symptoms, inhibited Helicobacter pylori, and reduced gastric mucosal inflammation, positioning SHT as a promising treatment for CAG. Explore the detailed findings of this study to learn more about the effectiveness of SHT: https://ow.ly/126550TkMHB #ShuganHeweiTherapy #TraditionalChineseMedicine #ChronicAtrophicGastritis #LiverQi #MedicalResearch #ChineseMedicine #Gastroenterology #Healthcare #ChineseMedicineAndCulture

Today we’ve crossed an exciting milestone with the first scientific publication of our clinical data supporting the therapeutic potential of #senolytics in providing long-lasting, disease-modifying intervention in vision loss.     Published in the Nature Medicine journal, the research provides mechanistic evidence that eliminating #senescent cells in the retina can potentially treat and reverse the hallmarks of #DME, an approach that UNITY is clinically investigating with the senolytic candidate #UBX1325.     We are honored to contribute to the growing field of senolytic research and bring us one step closer to providing new therapies for patients living with DME. #ReimagineAging    Read more: https://bit.ly/3SqYcjT

We are proud to announce that our latest research has been published in the "International Journal of Molecular Sciences." This work focuses on the dynamics of Aortic Stenosis, revealing the significant roles played by fibrosis, myocardial steatosis, myostatin, and ceramides. #AorticStenosis #CardiacResearch #MolecularSciences MDPI

The team from Chondrometrics GmbH and the Research Program for Imaging at Paracelsus Medizinische Privatuniversität in #Austria is excited to meet you at the OARSI - Osteoarthritis Research Society International Conference 2024 in #Vienna. It is represented by Susanne Maschek (Chief of Human Resources and Quality Control), Wolfgang Wirth (Chief Technical Officer and Chief of Quality Control), Clemens Heistracher (PhD Student), and Felix Eckstein (CEO & CMO). Please join us for Oral Presentation No. 20 at the Imaging Session on Friday, April 19th, at 9:45 a.m., and for a review presentation at the China-Germany-Night on the same day at 6:45 p.m. Also feel free do drop by our posters No. 84 and 90 (#AdvancedBioinformatics), No. 204 (#Biomechanics & #Gait), and No. 491, 492, and 493 (#Imaging) displayed during the two #PosterSessions. We look forward to engaging in interesting scientific discussions or simply having a friendly chat. Enjoy #Vienna! #Chondrometrics, #ParacelsusMedicalUniversity, #OARSIConference, #WorldCongress, #Osteoarthritis, #Research, #ClinicalTrial, #Reading, #Cartilage, #DMOAD, #Segmentation, #T2, #Diabetes, #SensitivityToChange, #MagneticFieldStrength, #JSW, #SexualDimorphism